67 results about "Myonectin" patented technology

Laminin and specific laminin-derived protein fragments are disclosed as potent inhibitors of Alzheimer's disease type amyloidoses. A specific region is identified within laminin which interacts with the Alzheimer's disease beta-amyloid protein and contributes to the observed inhibitory and therapeutic effects. A prominent ~130 kilodalton band in laminin was found in human serum and cerebrospinal fluid which primarily interacted with Abeta as determined by ligand blotting methodology. This ~130 kilodalton laminin fragment is known as the E8 fragment and is also believed to consist of the globular domains of the laminin A chain. The interaction of specific laminin fragments such as the newly discovered ~130 kDa protein is believed to bind Abeta in biological fluids and keep it in a soluble state.

Described herein are anti-MCAM antibodies and antigen binding fragments thereof that are capable of inhibiting the interaction between MCAM and its ligand, a protein comprising a laminin α-4 chain. These anti-MCAM antibodies and antigen binding fragments thereof may be useful for, for example, treating inflammatory conditions characterized by the infiltration of MCAM-expressing cells into a site of inflammation in the body.

The present disclosure related to isolated laminin-521, methods for making recombinant laminin-521, host cells that express recombinant laminin-521, and compositions containing laminin-521. Laminin-521 can maintain stem cells in vitro pluripotency, enable self-renewal, and enable single cell survival of human embryonic stem cells. When pluripotent human embryonic stem cells are cultured on plates coated with a matrix of recombinant laminin-521 (laminin 11), in the absence of differentiation inhibitors or feeder cells, the embryonic stem cells proliferate and maintain their pluripotency. It has also been discovered that human recombinant laminin-521 (laminin-11) provides single cell survival of stem cells after complete dissociation into a single cell suspension. Useful cell culture mediums containing at most 3.9 ng/ml of beta fibroblast growth factor (bFGF) are also described herein.

Glossy ganoderma as a traditional Chinese medicine is called immortal grass since ancient times and known as the ability to treat various diseases; a pair of lingzhiol A optical enantiomers is purified from ganoderma lucidum, and the lingzhiol A optical enantiomers have obvious effects on inhibiting rat renal mesangial cell strains induced by high glucose to generate reactive oxide species, IL-6, fibronectin and IV type collagen, and also can obviously inhibit the phosphorylation of the renal tubular epithelial cell Smad3 induced by TGF-beta1, so that the application prospect of the compound in preparation of medicines for treating diabetic nephropathy and chronic nephropathy is shown.

The invention provides berberine-containing serum-free medium for mesenchymal stem cells, comprising a DMEM basic medium and further comprising, by concentration, 5-110mg/L berberine, 3-20mg/ml basic fibroblast growth factors, 3-20mg/ml epidermal growth factors, 1-10Mug/mL glutathione, 1-10mg/ml recombinant human insulin, 5-15mg/ml human serum albumin, 1-10Mug/mL transferrin, 5-15mg/L fibronectin, 5-30mg/L putrescine, 0.37-4mg/L aminoethanol, 10-50Mug/mL hydrocortisone, and 0.02-0.2mg/ml sodium pyruvate. The invention belongs to the technical field of stem cells; the medium has good cell adherence, high cell proliferation rate and capable of delaying decline phase of MSCs (mesenchymal stem cells) and prolong growth period of the cells.

The present invention relates to the immunotherapB of cancer, in particular several tumor entities including hematological malignancies. The present invention relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class I or II molecules of human oncofoetal antigen immature laminin receptor (OFA/iLR), which can be used in vaccine compositions for eliciting anti-tumor immune responses.

Disclosed is the novel myokine known as myonectin (CTRP15), an isolated nucleic acid encoding the myonectin (CTRP15) gene, and the amino acid sequence encoding the myonectin (CTRP15) protein. Methods of isolation of the nucleic acid, protein, polypeptides and methods of making antibodies to the myonectin (CTRP15) protein are provided. The use of myonectin (CTRP15) in the modulation of lipid and/or glucose metabolism, suppressing the expression of autophagy genes, inhibiting LC3 lipidation and autophagosome-dependent p62 degradation, and activating the Akt/mTOR pathway is also provided.

The invention belongs to the technical field of medicine, and relates to a hexamethoxyflavanone-rhamnosyl-rhamnoside and application thereof. The hexamethoxyflavanone-rhamnosyl-rhamnoside is prepared by the following steps: carrying out solvent extraction and extraction separation on murraya jasminorage, carrying out silica gel column separation, carrying out further separation by semipreparative chromatography, concentrating, and carrying out freeze-drying to obtain the finished hexamethoxyflavanone-rhamnosyl-rhamnoside product. The antitumor activity evaluation detects that the hexamethoxyflavanone-rhamnosyl-rhamnoside has low cytotoxicity; the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on the adhesion of colon cancer cells HT-29 and Fn (fibronectin) and the adhesion of HUVECs (human umbilical vein endothelial cells); the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on migration capacity (scratch heating experiment) and invasion capacity of HT-29; and the hexamethoxyflavanone-rhamnosyl-rhamnoside has obvious inhibiting effects on mouse in-vivo B16-F10 lung transfer. Therefore, the hexamethoxyflavanone-rhamnosyl-rhamnoside has tumor transfer inhibition activity, can be used for preparing anticancer drugs, and has favorable development and application prospects.

It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiareteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease which involves the step of qualitatively or quantitatively measuring the degree of the binding of a test compound to a 67 kDa laminin receptor, and judging that the test compound is a drug having an effect of inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, a nerve protecting effect, an antiallergic effect, an antiareteriosclerotic effect and/or an effect of inhibiting infection with Creutzfeldt-Jakob disease in the case where it is found out by the results of the measurement that the test compound binds to the 67 kDa laminin receptor, and a drug obtained thereby.

The invention provides a gel composition, biological scaffold gel as well as a preparation method and application of the biological scaffold gel. The gel composition is prepared from polyethylene glycol (PEG), collagen, laminin, RGD polypeptide, B27, N2, N-acetylcystine, Nicotinamide, a Wnt signaling pathway agonist, an epidermal growth factor and a ROCK inhibitor. The biological scaffold gel comprises the following components according to final concentration: 0.01-0.5 g/ml of PEG (Polyethylene Glycol); the content of collagen is 0.02 to 0.5 g/ml; the concentration of the laminin is 0.05 to 100 ng/ml; b27, 0.5 to 5 *; n2, 0.5 to 5 *; the concentration of the N-acetylcystine is 0.1 to 50 [mu] M; the concentration of the Nicotinamide is 10 to 200 [mu] M; the concentration of the Wnt signal channel agonist is 25 to 500 ng/ml; eGF (Epidermal Growth Factor) with the concentration of The concentration of the ROCK inhibitor is 0.5 ng/ml to 100 ng/ml; the concentration of the RGD polypeptide is 0.1 mg/ml to 1 mg/ml; all the components are dissolved in a buffer solution or a basic culture medium. According to the method, 3D culture of cells and tissues can be efficiently carried out, and formed 3D cultures such as cell clusters and organoids can simulate in-vivo three-dimensional tissue structures and gene expression characteristics.